Special Issue "Competitive Advantage Strategies for Healthcare Industry"

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Care Sciences & Services".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editors

Prof. Dr. Munjae Lee
E-Mail Website
Guest Editor
Department of Medical Humanities and Social Medicine, Ajou University School of Medicine, Suwon 16499, Korea
Interests: healthcare management; medical device industry; digital healthcare; technology commercialization; health policy
Special Issues and Collections in MDPI journals
Dr. Kyu-sung Lee
E-Mail Website
Guest Editor
Department of Medical Device Management and Research, SAIHST, Sungkyunkwan University, Seoul 06351, Korea
Interests: community care; health management; healthcare strategy; benign prostatic hyperplasia

Special Issue Information

The healthcare industry is an aggregation and integration of sectors within the economic system that provides goods and services to treat patients with curative, preventive, rehabilitative, and palliative care. It includes the generation and commercialization of goods and services for maintaining and re-establishing health. The modern healthcare industry includes three essential branches, services, products, and finance, and may be divided into many sectors and categories. The industry depends on interdisciplinary teams of trained professionals and paraprofessionals to meet the health needs of individuals and populations.

The main objective of this Special Issue is to advance the fields of the healthcare industry and innovation management. Thus, papers submitted for the Special Issue should empirically or quantitatively address the valuable implications of the healthcare industry.

Dr. Munjae Lee
Dr. Kyu-sung Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • strategy 
  • healthcare industry 
  • medical device industry 
  • pharmaceutical industry 
  • biotechnology 
  • digital health 
  • health management 
  • interdisciplinary

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Influence of ESGC Indicators on Financial Performance of Listed Pharmaceutical Companies
Int. J. Environ. Res. Public Health 2021, 18(9), 4556; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18094556 - 25 Apr 2021
Viewed by 757
Abstract
The pharmaceutical industry, concerned about the impact of its activity, has integrated responsible principles and practices with a view to improving its sustainable and financial performance. This study analyzes the relationship between environmental, social, governance, and controversy indicators and financial performance, measured through [...] Read more.
The pharmaceutical industry, concerned about the impact of its activity, has integrated responsible principles and practices with a view to improving its sustainable and financial performance. This study analyzes the relationship between environmental, social, governance, and controversy indicators and financial performance, measured through return on equity (ROA), return on assets (ROE), and Tobin’s Q, which are applied to the listed companies in the Nasdaq US Smart Pharmaceuticals Index. This index is composed of 30 international companies with a presence at the global level. All the data have been extracted from the Thomson Reuters database. The analysis was performed using structural equation modeling implemented with partial least squares. The results confirm the positive relationship between the construct composed of environmental, social, and governance (ESG) indicators and the aforementioned financial ratios. Additionally, a positive relationship of the controversy indicator with Tobin’s Q is supported. This suggests that the pharmaceutical multinationals focus their investments in sustainability on ESG and pay attention to controversies to boost the visibility of the company and thus increase its value. These conclusions confirm that investing in ESG is a profitable strategy. It is also relevant for managers as it increases the profits and the market value of multinational pharmaceutical companies. Full article
(This article belongs to the Special Issue Competitive Advantage Strategies for Healthcare Industry)
Show Figures

Figure 1

Article
Administration of Strategic Agreements in Public Hospitals: Considerations to Enhance the Quality and Sustainability of Mergers and Acquisitions
Int. J. Environ. Res. Public Health 2021, 18(8), 4051; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18084051 - 12 Apr 2021
Viewed by 743
Abstract
Merger processes between hospitals have high benefit potential for patients, staff and managers. This integration of health centres can improve the quality and safety in patient care. Additionally, cooperative processes enhance the sustainability of the health system, by increasing team spirit, giving innovative [...] Read more.
Merger processes between hospitals have high benefit potential for patients, staff and managers. This integration of health centres can improve the quality and safety in patient care. Additionally, cooperative processes enhance the sustainability of the health system, by increasing team spirit, giving innovative ideas and improving staff satisfaction. In this article, the critical factors for successful hospital mergers and acquisitions in the Public Health System were considered to develop a brief guide to help with the organisation of a merger process. Five sections were designed: Strategic administration and objectives, Staff management, New hospital complex structure, Processes and Results. This guide facilitates the communication between a variety of stakeholders, thus improving the engagement between all members of the new healthcare system. This could be particularly important for countries with large regional variance in the organisation of health care and resources. Full article
(This article belongs to the Special Issue Competitive Advantage Strategies for Healthcare Industry)
Article
Competitive Revenue Strategies in the Medical Consumables Industry: Evidence from Human Resources, Research and Development Expenses and Industry Life Cycle
Int. J. Environ. Res. Public Health 2021, 18(6), 3180; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18063180 - 19 Mar 2021
Viewed by 539
Abstract
This study attempted to explore the competitive advantage strategies of the medical consumables industry (MCI) from the perspectives of human resources, research and development (R&D) and the industry life cycle. As one of the essential branches of modern medical device industry, the MCI [...] Read more.
This study attempted to explore the competitive advantage strategies of the medical consumables industry (MCI) from the perspectives of human resources, research and development (R&D) and the industry life cycle. As one of the essential branches of modern medical device industry, the MCI has developed rapidly in recent years as global demand for medical consumables has shown continual growth, but it also faces market uncertainty. This study took Taiwan’s small/medium medical consumables enterprises (SMMCEs) as a sample, and used the translog revenue function to study the competitive advantage of the MCI through human resource and R&D investment strategies and the stage characteristics of the industry life cycle curve. The results showed that the various human resources and R&D expenses of the small/medium medical consumables industry (SMMCI) can interact with each other to influence total revenue and that the SMMCI needs more varied types of human resources to enhance its competitive advantage. The total revenue of the SMMCI decreased as education inputs rose, but it increased along with increases in the number of employee and R&D inputs. Observed from the life cycle curve of the SMMCI, total revenue increased rapidly during the startup and growth stages, increased slowly during the maturity stage, and decreased during the decline stage. Finally, we put forward competitive advantage strategies and management suggestions for medical consumables enterprises (MCEs). We are the first to document the life cycle curve and competitive advantage strategies of the MCI, thereby contributing to the related literature. Full article
(This article belongs to the Special Issue Competitive Advantage Strategies for Healthcare Industry)
Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: The restructuring of China’s pharmaceutical industry under China’s governmentality
Authors: Woojong Moon
Affiliation: college of nursing, Hanyang University in Korea
Abstract: In China’s national focus on rapid economic growth since its market-oriented transition in the early 1980s, the field of health care and medicine was ignored to a great extent. Various social and health problems emerged accordingly. Against this background, the SARS outbreak occurred in 2002 and finally led China to the health care reform and the restructuring of the pharmaceutical industry. China’s government has exerted its controlling and hegemonic power on the industrial restructuring process. This study examines the Chinese government-led restructuring of the pharmaceutical industry with Foucault’s concept of governmentality. According to Foucault, governmentality is intimately related to power relations and ruling strategy to configure the health, social, and economic lives of individuals and populations in a specific way. I argue that the concept of governmentality can be applied to corporations in a similar way. This study shows that China’s pharmaceutical industrial restructuring has proceeded under the differential governmentality between domestic and foreign pharmaceutical companies and has been strengthened for the Chinese people’ health, China’s desire for the global market, and economic nationalism. In sum, China’s governmentality works on the pharmaceutical industry ultimately for China’s state legitimacy.

Back to TopTop